Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Bayer Animal Health Announces the Launch of Advantage® II and K9 Advantix® II

January 31, 2011 By Bio-Medicine.Org

SHAWNEE, Kan., Jan. 31, 2011 /PRNewswire/ — Bayer Animal Health
announced this month at the North American Veterinary Conference,
the availability of its new products:  Advantage® II for
cats and dogs, and K9 Advantix® II for dogs.  These
products combine the adulticidal properties of the original
formulations of Advantage® Topical Solution and K9
Advantix®, with the insect growth regulator (IGR) pyriproxyfen,
which inhibits the development of flea eggs and kills flea larvae.
 As a result, Advantage® II and K9 Advantix® II kill
all flea life stages and prevent fleas on a treated dog from
infesting the home.  These products will be available in March
2011.  

Pyriproxyfen, the added compound in Advantage® II and K9
Advantix® II, interferes with the hormone signaling of growing
insects so that fleas in immature stages are unable to mature.
 The hormone pathway that pyriproxyfen targets is specific to
insects and does not affect mammals.  

“Adding pyriproxyfen to the original formulations of
Advantage® Topical Solution and K9 Advantix® gives an added
layer of protection to our customers’ pets and their pets’
surroundings.  It interrupts the flea life cycle at multiple
stages, and prevents reinfestation,” said Peter Ryan, Vice
President & Head, Companion Animal Business Unit, Bayer Animal
Health.

Advantage® II and K9 Advantix® II have adulticidal,
larvicidal and ovicidal properties, killing adult fleas and
preventing the emergence of new ones.  Disrupting the flea
life cycle through different active ingredients and modes of action
is often referred to as integrated flea control (IFC).
 Imidacloprid quickly paralyzes a flea’s mouthparts and kills
fleas through contact, so fleas don’t have to bite your pet to die.
By protecting pets from fleas, imidacloprid has been shown to
reduce the incidence of certain conditions including flea al

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech